TAM
CYTO

Tiverton Asset Management’s Altamira Therapeutics Ltd CYTO Stock Holding History

Tiverton Asset Management’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-21
Closed -$9.62M – 133
2014
Q3 		$9.62M Buy
+21
New +$10.4M 0.22% 95

Other funds holding CYTO

ABI
Adamant Biomedical Investments Zurich, Switzerland $418M AUM
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tiverton Asset Management's CYTO Position: Q4 2014 in Review

Tiverton Asset Management sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2014, closing a stake of 21 shares — an estimated $9.62M sold.

Tiverton Asset Management first reported a position in CYTO in Q3 2014 and held it in 1 quarter. The position peaked at $9.62M in Q3 2014. 6 funds tracked by Wall St. Rank hold CYTO as of Q4 2014.

  • Tiverton Asset Management reported no remaining Altamira Therapeutics Ltd position as of Q4 2014 after selling out during the quarter.
  • Tiverton Asset Management sold 21 Altamira Therapeutics Ltd shares in Q4 2014, an estimated $9.62M.
  • Tiverton Asset Management first reported a position in Altamira Therapeutics Ltd in Q3 2014 and held it in 1 quarter.
  • Tiverton Asset Management's Altamira Therapeutics Ltd position peaked at $9.62M in Q3 2014.
  • 6 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2014.

Based on Tiverton Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.